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Introduction
The Human Microbiome Project launched in 2007 
approximated the human microbiome’s complex-
ity and led to significant growth in understanding its 
role in health and disease (Moffatt and Cookson 2017). 
In 2020, an international panel of experts proposed 
an updated definition of the microbiota, describing it as 
the assemblage of living microorganisms belonging to 
different kingdoms (Prokaryotes [Bacteria, or Archea], 
Eucaryotes [e.g., Protozoa, Fungi, and Algae]) (Berg 
et al. 2020). The human microbiome represents not 
only the entire community of commensal, symbiotic, 
and pathogenic microorganisms but also their “theatre 
of activity”, involving the whole spectrum of molecules 
produced by the microorganisms (their structural ele-
ments and metabolites), and molecules produced by 
coexisting hosts embedded in the environmental habitat 
(Berg et al. 2020). This complex ecosystem plays a fun-
damental role in controlling most aspects of physiology. 
Inhabiting various anatomical body sites, such as skin, 
mucosa, the gastrointestinal tract, and the respiratory 
tract, the microbiota is crucial in regulating the home-
ostasis and metabolism of hematopoiesis, inflamma-
tion, and immunity of its host (Moffatt and Cookson 
2017). The microbiome’s size and composition evolve in 
response to environmental and host factors, and in any 
imbalance, a negative impact can be seen upon human 
health (Ogunrinola et al. 2020). Shifts in the microbiota 
composition may lead to dysbiosis by decreasing the 
number of symbionts and increasing potential danger-
ous pathogens. Microbial dysbiosis has been found to be 
involved in a growing list of human diseases, including 
chronic respiratory diseases (Paudel et al. 2020).
Chronic respiratory diseases account for high mor-
bidity and mortality, with asthma, chronic obstructive 
pulmonary disease (COPD), and cystic fibrosis (CF) 
being the most prevalent globally (Paudel et al. 2020). 
Even though the diseases increase in prevalence, the 
exact underlying mechanisms have still not been fully 
understood. Despite their differences in nature, patho-
physiologies, and clinical phenotypes, a growing body 
of evidence indicate that the presence of lung micro-
biota has the potential to shape the pathogenic processes 
underlying chronic inflammation typically observed in 
the course of the diseases (Dima et al. 2019; Loverdos 
et al. 2019). The characterization of the lung micro-
biota may therefore shed new light on the pathogenesis 
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of these diseases. Specifically, in chronic respiratory 
tract diseases, the human microbiota may contribute 
to the disease’s development and severity. The present 
review aims at exploring the role of the microbiota in 
chronic pulmonary diseases, especially COPD, asthma, 
and CF, and, in particular, the possible mechanisms of 
airway microbiome contributing to the pathogenesis 
of these diseases. The main hypothesis is that inter-
actions between the bacterial microbiome and host 
inflammation are related to chronic lung diseases and 
their exacerbations. For this purpose, a comprehensive 
literature search was conducted using PubMed to col-
lect current studies concerning lung microbiome in 
COPD, asthma, and CF. The following keywords were 
used 1. microbiome and chronic pulmonary disease; 
2. asthma; 3. COPD; 4. CF; 5. microbiota and immu-
nity; 6. airway microbiome; 7. airway microbiota and 
combinations thereof.
Healthy lung microbiota
A microbiome analysis based on 16S rRNA sequenc-
ing has identified unique microbiota in organs previ-
ously considered sterile, such as the lower respiratory 
tract. Currently, there is no doubt that the mucous 
membrane of the lungs has its own resident microbi-
ome (Huffnagle et al. 2017). Moreover, increasing evi-
dence indicates that pulmonary microbiota, acting on 
resident immune cells, plays a key role in maintaining 
homeostasis in the organs (Dickson et al. 2013).
Lungs, being constantly in contact with environ-
mental air, full of microorganisms and inhaled particles, 
are at the frontline of immunity (Wang et al. 2017; 
Sommariva et al. 2020). The lower respiratory tract is 
a rather hostile environment for microbes. Ciliary epi-
thelium and numerous mucin-releasing secretory cells 
of bacteriostatic properties mainly line it, creating an 
immune barrier. Moreover, the immunity of healthy 
lungs is conditioned by the presence of lung-resident 
lymphocytes and alveolar macrophages, which addition-
ally protects them against external threats (Malinowska 
et al. 2017; Wang et al. 2017). In addition to its essen-
tial role in immunity against pathogens, perhaps the 
pulmonary immune system’s most important func-
tion is to maintain a state of immunotolerance to non-
dangerous environmental particles and self-antigens 
(Ramírez-Labrada et al. 2020; Sommariva et al. 2020). 
Cross-talk between alveolar macrophages, dendritic 
cells, and regulatory T cells (Treg) is the most critical 
to maintaining an immunological tone of the airways 
(Lloyd and Marsland 2017; Ramírez-Labrada et al. 2020; 
Sommariva et al. 2020). Of note, depletion of naturally 
occurring regulatory cells is characteristic of many 
chronic inflammatory diseases, including allergies, CF, 
and COPD, and their downregulation are strongly con-
nected with disease progression (Ramírez-Labrada et al. 
2020; Sommariva et al. 2020). Accumulating evidence 
shows that resident pulmonary Treg cells’ functional-
ity can be significantly shaped by local lung microbiota 
(Ramírez-Labrada et al. 2020; Sommariva et al. 2020). 
Lung microbiota is a relatively small bacterial com-
munity containing 103–105 cells/g of bronchial tissue. 
Comparatively, colon microbiota, which represents the 
most abundant ecosystem, comprises 1011–1012 cells/g 
of luminal content (Loverdos et al. 2019). Similar to 
other body sites, lungs present a complex bacterial 
community (Sommariva et al. 2020). According to 
numerous studies, the most common bacterial phyla 
that constitute the lung microbial ecosystem belong to 
Bacteroides and Firmicutes genera. It was also found 
that oral commensals, such as Prevotella, Veilonella, 
and Streptococcus, are the most prominent in healthy 
individuals’ lungs (Ramírez-Labrada et al. 2020; Som-
mariva et al. 2020; Xu et al. 2020). This neutral com-
munity is acquired mostly during microaspiration of 
pharyngeal particles or direct migration along airway 
mucosa, and all their members equally participate in 
creating the regional growth conditions, i.e., the lung 
microenvironment (Ramírez-Labrada et al. 2020). Thus, 
it appears that the microbes’ composition in the lungs 
is dynamic, mainly determined by the balance between 
microbial migration from the upper respiratory tract 
during microaspiration, elimination by coughing, 
mucociliary clearance, and immune system activity 
(Ramírez-Labrada et al. 2020; Sommariva et al. 2020; 
Xu et al. 2020). Different external and internal factors 
can influence the composition of the lung microbiome. 
Age, nutrition, lifestyle, pollution or tobacco smoke, 
inherited genes, and underlying diseases all can shape 
the type and number of lung microbiota, eventually 
leading to dysbiosis (Ogunrinola et al. 2019). 
The respiratory microbiota both impacts and is 
impacted by immunity and disease. To avoid chronic 
inflammation under healthy condition, the lung micro-
biota has a fundamental role in shaping pulmonary 
immune tolerance. Microbes boost and calibrate innate 
and adaptive immunity, contribute to metabolic activi-
ties, and provide resistance to invasion by respiratory 
pathogens. Commensals can promote the establish-
ment of a hostile environment and protect its host 
from pathogenic colonization (Ramírez-Labrada et al. 
2020). This growth restriction may be caused by several 
mechanisms, such as altering of nutrient availability 
and production of antimicrobial metabolites (Ramírez-
Labrada et al. 2020). Aside from the fact that microbiota 
can act on invasive microbes preventing their growth 
and spread, it plays a pivotal role in regulating immune 
tolerance in the lung environment. For homeostasis to 
be effectively managed, a balance must be maintained 
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between several factors, including Th cell activation 
and suppression by regulatory Treg cells (Belkaid and 
Hand 2014; Belkaid and Harrison 2017). As mentioned 
before, a local lung commensal can significantly modu-
late the activity of resident pulmonary immune cells. 
Indeed, microbiota participates in shaping an immune 
tolerant environment influencing the recruitment and 
activation of Treg cells as well as macrophages and 
tolerogenic dendritic cells (Ramírez-Labrada et al. 2020; 
Sommariva et al. 2020). 
An optimal microbiota-host interaction impacts the 
formation of a symbiotic relationship between com-
mensal bacteria and their host. Beneficial as microbiota 
may be in maintaining health, its perturbation disrupts 
homeostatic processes promoting dysfunction and dis-
ease (Sommariva et al. 2020).
Lung microbiota in chronic pulmonary diseases
Inflammation represents a host response to many 
harmful stimuli, including pro-inflammatory mediators, 
environmental toxins, and chronic infection (Huffnagle 
et al. 2017). In contrast to acute inflammatory response, 
chronic inflammation represents a long-term reaction, 
characteristic of predominant recruitment of mononu-
clear leucocytes. A growing body of evidence suggests 
that the dysregulation of the human lung microbiota is 
involved in shaping the pathogenetic processes underly-
ing nearly all kinds of chronic inflammatory respiratory 
diseases (Wang et al. 2017; Loverdos et al. 2019). This 
has been achieved by culture-independent sequencing 
techniques that in patients with chronic pulmonary dis-
eases microbiota can be found that profoundly differs 
from that of healthy lungs, which indeed, determines 
a chronic inflammatory status. The reason for the prob-
lem – inflammation –  suggests that microbiota can 
modulate the environment, in which it lives. Admittedly, 
disturbances in the microbial community can drasti-
cally change the local growth conditions by changing the 
resident immune cells’ activation state. During chronic 
inflammation, the lung habitat becomes unstable, and its 
species composition changes from “healthy” to a “patho-
genic” state (Kovaleva et al. 2019). 
Although the role of specific bacteria in the devel-
opment of specific lung pathologies is still being estab-
lished, a shift often occurs towards Proteobacteria the 
bacterial class of common lung-associated Gram-
negative pathogens (mostly Neisseria, Moraxella, and 
Haemophilus) (Huffnagle et al. 2017; Sommariva et al. 
2020). Particular metabolites and toxins with immuno-
regulatory properties are released, and other permis-
sive niches for other species to reside there are created 
(O’Dwyer et al. 2016; Toraldo end Conte 2019). There is 
growing evidence that their metabolites, toxins, and cell 
lysis products by enriching the local microenvironment 
activate the host’s inflammatory cells and, therefore, 
contribute to lung diseases’ pathogenesis (Huffnagle 
et al. 2017; Sommariva et al. 2020). 
Key environmental factors that influence commen-
sal bacteria growth and survival, such as temperature, 
pH, oxygen tension, and host immune cells, change 
dramatically. Nutrients, limited during the steady-state, 
are made available in abundance with the introduc-
tion of mucus and vascular permeability (Huang et al. 
2017; Sommariva et al. 2020). These profound changes 
in the community composition of the respiratory 
microbiota, directly influencing the immune system 
regulation, are now believed to be involved in a rapid 
increase of chronic inflammatory diseases (Belkaid 
and Hand 2014; O’Dwyer et al. 2016). It must also be 
considered that numerous byproducts of inflammation: 
catecholamines, and inflammatory cytokines, positively 
influence the growth and survival of some potentially 
pathogenic groups of bacteria, especially members of 
Proteobacteria. During chronic inflammation, bacteria 
that can benefit from inflammation outcompete bacte-
ria that cannot thrive in such an unfavorable environ-
ment, resulting in a reduction in microbiome diversity 
(Huffnagle et al. 2017; Loverdos et al. 2019).
The basis of chronic lung diseases is a variety of bio-
logical and genetic mechanisms and dysbiosis, which 
significantly contributes to injury to the host. The 
microbiota’s metabolites and toxins are responsible for 
the changes in maintaining the steady-state of the lung 
microenvironment. However, it is not a single species 
or bacterial product responsible for this imbalance, but 
the entire cascade of events is an underlying cause of 
lung diseases. Thus, pathological changes in the com-
position and abundance of the lung microbiota might 
contribute to and result from chronic inflammation 
(Huang et al. 2017; Huffnagle et al. 2017; Sommariva 
et al. 2020) (Fig. 1).
Fig. 1. A circle of dysbiosis and inflammation
in chronic pulmonary diseases.
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Airway microbiome in asthma
Asthma is a complex disease of the respiratory 
air ways characteristic of chronic inflammation in the 
lungs, reversible airflow obstruction, mucus over-
pro duc tion, and tissue neutrophilia or eosinophilia 
(Paudel et al. 2020). There is not a single cause of asthma 
(Kozik and Huang 2019). Existing data point to genetic 
and exogenous risks, including cigarette smoke, viral 
and bacterial infections, and obesity, associated with 
severe asthma and exacerbations of the disease (Kozik 
and Huang 2019; Paudel et al. 2020).
The role of the lung microbiome in the pathogenesis 
of asthma has not yet been fully elucidated. However, 
the most constant finding among lung microbiome 
studies is an observed increase in bacterial load and 
dominance of Proteobacteria, particularly Haemophi­
lus spp. and Moraxella catarrhalis (Castro-Nallar et al. 
2015; Noval Rivas et al. 2016; Loverdos et al. 2019). 
Dysbiotic communities may substantially contribute 
to the course or severity of the disease. On the other 
hand, a reduction in bacterial diversity could influ-
ence the inflammatory asthma phenotypes (Chung 
2017; Sverrild et al. 2017). Different studies have shown 
that in patients with neutrophilic asthma, the micro-
biota composition is altered, and organisms, such as 
M. catarrhalis, Haemophilus spp. and Streptococcus spp. 
predominate. Their presence is associated with severe 
airflow obstruction, longer asthma duration, and neu-
trophilic infiltration, possibly via Th-17 – driven mech-
anism (Chung et al. 2017; Sverrild et al. 2017; Kozik 
and Huang 2019; Goto 2020; Paudel et al. 2020). In 
patients with worse asthma symptoms, airway enrich-
ment with potentially pathogenic Proteobacteria mem-
bers correlates with the level of IL-8, the neutrophilic 
pro-inflammatory marker. Interestingly, neutrophilic 
asthma is also associated with inadequate response to 
the first-line corticosteroid treatment. In corticoster-
oid-resistant patients, an overgrowth of Haemophilus 
parainfluenzae has been noted. Moreover, Haemophilus 
influenzae and Tropheryma have been reported in spu-
tum samples of patients with poorly controlled severe 
cases (Simpson et al. 2016; Chung 2017). As inhaled 
steroids are a mainstay of the therapy, the involvement 
of particular bacterial genera in resistance mechanisms 
may explain the cause of steroidunresponsive asthma.
Eosinophilic asthma results from the activation of 
Th2 response that leads to airway infiltration by eosino-
phils. Here, in contrast to neutrophilic phenotype, 
microbiota’s role is less clear and more heterogeneous 
(Taylor et al. 2018; Barcik et al. 2020). As observed, 
eosinophil infiltration of bronchial tissue is associated 
with low bacterial burden and diversity (Denner et al. 
2016; Cait et al. 2018). The same studies found a nega-
tive correlation between Proteobacteria and Firmicutes 
and lung eosinophilia (Huang et al. 2015; Denner et al. 
2016; Cait et al. 2018). It is now suggested that fungi, 
such as Aspergillus spp. rather than bacteria play a more 
significant role in eosinophilic asthma. This finding 
is supported by the fact that fungi, being significant 
allergens, can induce a strong eosinophilic allergic 
reaction in asthmatic patients. Nevertheless, the role 
of fungal microbiota in asthma remains poorly under - 
stood (Durack et al. 2017; Kozik and Huang 2019; 
Loverdos et al. 2019).
Respiratory viruses, mainly rhinoviruses, are detec- 
ted in more than 75% of patients with acute exacerba-
tion of asthma. For a long time, the bacterial role in 
asthma exacerbations has not been considered, since 
traditionally, no microbes were grown from patients’ 
clinical specimens. Also, no clinical benefits of early 
antibiotic therapy were noticed in patients with acute 
exacerbation of the disease. However, culture-inde-
pendent approaches, surprisingly, demonstrated the 
presence of atypical bacteria, such as Mycoplasma 
pneumoniae and Chlamydia pneumoniae (Dickson et al. 
2014). However, their role in exacerbations of asthma is 
less clear than that of viral infections. It is believed that 
these bacterial pathogens may be somewhat involved in 
asthma persistence than exacerbations (Papadopoulos 
et al. 2011).
Airway microbiome in cystic fibrosis
Although cystic fibrosis (CF) is a multisystem dis-
ease, the disease’s most tremendous burden falls upon 
the respiratory tract, characteristic of chronic airway 
infection and inflammation (Cribbs and Beck 2016). 
Recent studies have demonstrated that the lung micro-
biome is associated with the pathogenesis of this disease.
Cystic fibrosis arises from mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) 
gene that is required for the homeostatic control of 
chloride ions in the lung. The CFTR gene’s role is cru-
cial, and its mutations lead to mucin overproduction 
along airways and disruption of the regular mucociliary 
activity and transport (Cribbs and Beck 2016; Françoise 
and Héry-Arnaud 2020). This defect also promotes 
polymicrobial proliferation and microbial imbalance 
along the respiratory tract, as mucin is a rich nutri-
tional resource, which can support bacterial growth 
(Françoise and Héry-Arnaud 2020). In CF, the subse-
quent activation of neutrophilic inflammatory response 
leads to uncontrolled inflammation and progressive 
lung disease that severely limits pulmonary function 
(LiPuma 2010; Belkaid and Hand 2014). Polymicrobial 
chronic airway infections, which are characteristic of 
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CF, lead to persistent inflammation and periodic epi-
sodes of acute pulmonary exacerbation. 
Traditionally, only a few bacteria have been associ-
ated with CF. Pseudomonas aeruginosa, Staphylococcus 
aureus, H. influenzae, and Burkholderia cepacia are the 
most often CF airway constituents (Belkaid and Hand 
2014; Surette 2014; Cuthbertson et al. 2020). However, 
next-generation sequencing significantly advanced our 
knowledge about bacterial communities within a CF 
lung. Lines of evidence now show that CF lung micro-
biome is more complex, polymicrobial, highly diverse 
with overexpression of Actinobacteria and Proteobacte­
ria, and potentially pathogenic anaerobes (Gillanders 
et al. 2011; Cuthbertson et al. 2020; Françoise and Héry-
Arnaud 2020). The changes in the bacterial community 
might play an essential role in CF airway microenviron-
ment condition. Bacteria within the CF lung contribute 
to horizontal gene transfer, especially in the presence 
of biofilm. They may affect the host by shedding differ-
ent bioactive molecules that interact with host cells in 
shaping immune response and triggering inflammatory 
cytokines and growth factors (Cribbs and Beck 2017). 
Microbial diversity is a marker of lung function 
(Françoise and Héry-Arnaud 2020). In CF, bacterial 
diversity correlates with the patient’s age, the disease 
stage, and recurrent antibiotic therapies. A  frequent 
broad-spectrum antibiotic therapy to treat pulmonary 
infections together with airway inflammation appears 
to be a significant driver of a fall in bacterial diversity 
that increases with age. This reduction is additionally 
associated with the establishment of species that are 
regarded as pathogens, usually, H. influenzae, S. aureus, 
and P. aeruginosa (Cox et al. 2010; Rogers et al. 2017; 
Françoise and Héry-Arnaud 2020). Consequently, 
the collapse in community diversity is associated with 
reduced lung function and disease progression (Cox 
et al. 2010). Data on strain changes in patients with 
pulmonary exacerbations remain unclear and contra-
dictory (Carmody et al. 2013; Surette et al. 2014; Acosta 
et al. 2017). Many authors indicate that a total load of 
bacteria does not generally change at exacerbation 
onset. They also noticed that exacerbations are not 
related to significant in microbial diversity changes, 
but the microbiota composition that was more diverse 
at baseline tended to change over time (Hoffman and 
Surette 2013). Some studies report that P. aeruginosa 
and anaerobes are the critical components of pulmo-
nary exacerbations. According to the observations of 
Carmody et al. (2013) facultatively anaerobic bacteria 
of the genus Gemella increased by 83% during exacer-
bation. Although the pathogenic potential of Gemella 
is not known, its abundance in patients during exacer-
bation makes it a potential biomarker candidate of the 
acute stage of the disease (Hoffman and Surette 2013).
Airway microbiome in chronic
obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD), 
one of the most prevalent respiratory diseases, is char-
acteristic of persistent symptoms and airway obstruc-
tion due to inflammation. Traditionally, culture-based 
methods of analysis of COPD samples frequently 
revealed H. influenzae, S. pneumoniae, M. catarrhalis 
and P. aeruginosa as the most prominent pathogenic 
bacteria involved in the pathogenesis of the disease. 
Recent use of high throughput 16S rRNA gene-based 
sequencing has provided additional evidence of the 
presence of dysbiosis in COPD. Culture-independ-
ent methods confirmed that in COPD, aerobic and 
anaerobic bacteria colonize the airways, with Pro­
teo bacteria (Haemophilus spp.) being more common 
than Bacteroides (Prevotella spp.) being significantly 
reduced (Einarsson et al. 2016; Haldar et al. 2020). 
In addition, in stable COPD, a higher level of colo-
nization with potentially pathogenic bacteria, such 
as H. influenzae, S. pneumonia, and M. catarrhalis is 
associated with a greater chance of exacerbation and 
a  more severe airflow obstruction (Martinez et al. 
2013; Ditz et al. 2020). These bacteria are found in 
more than 75% of cases and are regarded as a “core” 
pulmonary microbiome in COPD (Martinez et al. 2013; 
Einarsson et al. 2016).
The disease is characteristic of a chronic inflam-
matory state, and bacteria colonizing COPD patients’ 
airways are believed to participate in this dysregula-
tion and provoke the host inflammatory response 
(Dima 2019; Haldar et al. 2020). Even at the state of 
bacterial colonization in stable COPD, many authors 
have reported excessive inflammation. In patients with 
COPD, persistent neutrophilic inflammation likely rep-
resents a local host immune response to chronic micro-
bial colonization (Burgel et al. 2017). In addition, it has 
been confirmed that the profile of colonization-induced 
inflammation is similar to that observed during exac-
erbation. Therefore, it is likely that chronic microbial 
infection with potential bacterial pathogens serves as an 
activator of an immune response (Martinez et al. 2013; 
Wang et al. 2016; Burgel et al. 2017). 
In patients with acute exacerbation, augmenting 
neutrophilic or eosinophilic inflammation is typically 
observed. As expected, bacteria-associated COPD 
exacerbations are associated with airway neutrophilia, 
accompanied by elevated levels of the primary media-
tors of inflammation, including IL-1β, IL-8, and TNF. 
Subsequently, an increased number of neutrophils and 
inflammatory markers in the airways can cause signifi-
cant damage to the respiratory tissue (Burgel et al. 2017; 
Ditz et al. 2020). 
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Conclusions and perspectives
While the study of the exact influence of the micro-
biome on lung health is still a relatively new field, it is 
clear that respiratory microbiome changes accompany 
chronic lung diseases of a non-infectious etiology, as 
previously believed. The composition of the lung micro-
biome is increasingly well characterized, and a specific 
spectrum of pathogenic microorganisms observed in 
association with several chronic respiratory diseases 
such as asthma, cystic fibrosis, and chronic obstruc-
tive pulmonary disease is already described. Indeed, 
the lung microbiome in chronic pulmonary diseases 
has a dynamic nature and is influenced by many factors, 
such as age, environmental exposure, treatment, etc.
It is also now becoming clear that chronic respira-
tory diseases’ pathogenesis is a cascade of events in 
a  self-amplifying cycle of altered microbial growth 
conditions, respiratory dysbiosis, and airway inflam-
mation. In this cycle of events, changes in lung micro-
bial community composition and abundance provoke 
airway inflammation, injuring the delicate lung tissue. 
And then, inflammation of the airways alters microbial 
environmental growth conditions promoting dysbiosis. 
Lung microbiota does not seem to be the only micro-
bial factor contributing to chronic pulmonary diseases. 
The gut microbiota’s influence on lung immunity has 
been well documented and linked to disease develop-
ment in the lungs with immune response changes when 
the gut microbiota community is altered (Pulvirenti 
et al. 2019). Mounting evidence indicates that the 
immune cells and cytokines induced by the gut micro-
biota components or metabolites, especially short-chain 
fatty acids (SCFAs), can modulate lung immunity and 
inflammatory responses, with specific taxa able to influ-
ence the pathogenesis of chronic pulmonary diseases 
(Samuelson et al. 2015; Cait et al. 2018). Although there 
is a growing body of evidence for the role of the gut/
lung axis in lung diseases, several unanswered questions 
still exist for its clinical relevance. 
Environmental factors such as pollution, cigarette 
smoke, antibiotics, and diet can also modulate micro biota 
composition and affect disease susceptibility. Indeed, it 
is broadly accepted that cigarette smoking and air pol-
lution are the most substantial risk factors for devel-
oping COPD (Allais et al. 2016). At the same time, an 
increased risk of asthma has been associated with micro-
bial dysbiosis in the gut in early life. Simultaneously, 
the use of antibiotics in children has also been impli-
cated in the development of asthma (Yang et al. 2019).
Although many of the underlying mechanisms are 
likely disease-specific, the microbiome’s exploration is 
promising and provides a solid background for devel-
oping innovative strategies for diagnostic, preventative, 
and therapeutic approaches.
Conflict of interest
The authors do not report any financial or personal connections 
with other persons or organizations, which might negatively affect 
the contents of this publication and/or claim authorship rights to 
this publication.
Literature
Acosta N, Whelan FJ, Somayaji R, Poonja A, Surette  MG, 
Rabin HR, Parkins MD. The evolving cystic fibrosis microbiome: 
a comparative cohort study spanning 16 years. Ann Am Thorac Soc. 
2017 Aug;14(8):1288–1297.
https://doi.org/10.1513/AnnalsATS.201609-668OC 
Allais L, Kerckhof FM, Verschuere S, Bracke KR, De Smet  R, 
Laukens D, Van den Abbeele P, De Vos M, Boon N, Brusselle GG, 
et al. Chronic cigarette smoke exposure induces microbial and 
inflammatory shifts and mucin changes in the murine gut. Environ 
Microbiol. 2016 May;18(5):1352–1363.
https://doi.org/10.1111/1462-2920.12934 
Barcik W, Boutin RCT, Sokolowska M, Finlay BB. The role of lung 
and gut microbiota in the pathology of asthma. Immunity. 2020 Feb 
18;52(2):241–255. https://doi.org/10.1016/j.immuni.2020.01.007 
Belkaid Y, Hand TW. Role of the microbiota in immunity and 
inflammation. Cell. 2014 Mar;157(1):121–141.
https://doi.org/10.1016/j.cell.2014.03.011
Belkaid Y, Harrison OJ. Homeostatic immunity and the microbiota. 
Immunity. 2017 Apr;46(4):562–576.
https://doi.org/10.1016/j.immuni.2017.04.008 
Berg G, Rybakova D, Fischer D, Cernava T, Vergès  MCC, 
Charles  T, Chen X, Cocolin L, Eversole K, Corral GH, et al. 
Microbiome definition re-visited: old concepts and new challenges. 
Microbiome. 2020 Dec;8(1):103.
https://doi.org/10.1186/s40168-020-00875-0 
Burgel P-R, Contoli M, López-Campos JL. Acute exacerbations 
of the pulmonary diseases. Sheffield (UK): European Respiratory 
Society; 2017. https://doi.org/10.1183/2312508X.erm7717 
Cait A, Hughes MR, Antignano F, Cait J, Dimitriu PA, Maas KR, 
Reynolds LA, Hacker L, Mohr J, Finlay BB, et al. Microbiome-
driven allergic lung inflammation is ameliorated by short-chain fatty 
acids. Mucosal Immunol. 2018 May;11(3):785–795.
https://doi.org/10.1038/mi.2017.75 
Carmody LA, Zhao J, Schloss PD, Petrosino JF, Murray S, 
Young VB, Li JZ, LiPuma JJ. Changes in cystic fibrosis airway micro- 
 biota at pulmonary exacerbation. Ann Am Thorac Soc. 2013 Jun; 
10(3):179–187. https://doi.org/10.1513/AnnalsATS.201211-107OC 
Castro-Nallar E, Shen Y, Freishtat RJ, Pérez-Losada M, Mani-
maran S, Liu G, Johnson WE, Crandall KA. Integrating microbial 
and host transcriptomics to characterize asthma-associated micro-
bial communities. BMC Med Genomics. 2015 Dec;8(1):50.
https://doi.org/10.1186/s12920-015-0121-1 
Chung KF. Airway microbial dysbiosis in asthmatic patients: A tar-
get for prevention and treatment? J Allergy Clin Immunol. 2017 
Apr; 139(4):1071–1081. https://doi.org/10.1016/j.jaci.2017.02.004 
Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, 
Karaoz U, Andersen GL, Brown R, Fujimura KE, et al. Airway 
microbiota and pathogen abundance in age-stratified cystic fibrosis 
patients. PLoS One. 2010 Jun 23;5(6):e11044.
https://doi.org/10.1371/journal.pone.0011044 
Cribbs SK, Beck JM. Microbiome in the pathogenesis of cystic 
fibrosis and lung transplant-related disease. Transl Res. 2017 Jan; 
179:84–96. https://doi.org/10.1016/j.trsl.2016.07.022 
Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW, 
Hampton TH, Ashare A, Elborn JS, De Soyza A, Carroll MP, et al. 
Microbiota and chronic lung inflammatory diseases1 31
Lung function and microbiota diversity in cystic fibrosis. Micro-
biome. 2020 Dec;8(1):45.
https://doi.org/10.1186/s40168-020-00810-3 
Denner DR, Sangwan N, Becker JB, Hogarth DK, Oldham J, 
Castillo J, Sperling AI, Solway J, Naureckas ET, Gilbert JA, et al. 
Corticosteroid therapy and airflow obstruction influence the bron-
chial microbiome, which is distinct from that of bronchoalveolar 
lavage in asthmatic airways. J Allergy Clin Immunol. 2016 May; 
137(5):1398–1405.e3. https://doi.org/10.1016/j.jaci.2015.10.017 
Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the 
bacterial microbiome in lung disease. Expert Rev Respir Med. 2013 
Jun;7(3):245–257. https://doi.org/10.1586/ers.13.24 
Dickson RP, Martinez FJ, Huffnagle GB. The role of the micro-
biome in exacerbations of chronic lung diseases. Lancet. 2014 Aug; 
384(9944): 691–702.
https://doi.org/10.1016/S0140-6736(14)61136-3 
Dima E, Kyriakoudi A, Kaponi M, Vasileiadis I, Stamou P, 
Koutsoukou A, Koulouris NG, Rovina N. The lung microbiome 
dynamics between stability and exacerbation in chronic obstructive 
pulmonary disease (COPD): Current perspectives. Respir Med. 2019 
Oct;157:1–6. https://doi.org/10.1016/j.rmed.2019.08.012 
Ditz B, Christenson S, Rossen J, Brightling C, Kerstjens HAM, 
van den Berge M, Faiz A. Sputum microbiome profiling in COPD: 
beyond singular pathogen detection. Thorax. 2020 Apr;75(4):338–344. 
https://doi.org/10.1136/thoraxjnl-2019-214168 
Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, 
Dyer AM, Israel E, Kraft M, Martin RJ, et al.; National Heart, 
Lung and Blood Institute’s “AsthmaNet”. Features of the bronchial 
bacterial microbiome associated with atopy, asthma, and responsive-
ness to inhaled corticosteroid treatment. J Allergy Clin Immunol. 
2017 Jul;140(1):63–75. https://doi.org/10.1016/j.jaci.2016.08.055 
Einarsson GG, Comer DM, McIlreavey L, Parkhill J, Ennis M, 
Tunney MM, Elborn JS. Community dynamics and the lower air-
way microbiota in stable chronic obstructive pulmonary disease, 
smokers and healthy non-smokers. Thorax. 2016 Sep;71(9):795–803.
https://doi.org/10.1136/thoraxjnl-2015-207235 
Françoise A, Héry-Arnaud G. The microbiome in cystic fibrosis 
pulmonary disease. Genes (Basel). 2020 May 11;11(5):536.
https://doi.org/10.3390/genes11050536 
Gillanders LJ, Elborn JS, Gilpin DF, Schneiders T, Tunney MM. 
The airway microbiome in cystic fibrosis: challenges for therapy. 
Therapy. 2011 Nov;8(6):645–660.
https://doi.org/10.2217/thy.11.81 
Goto T. Airway microbiota as a modulator of lung cancer. Int J Mol 
Sci. 2020 Apr 26;21(9):3044.
https://doi.org/10.3390/ijms21093044 
Haldar K, George L, Wang Z, Mistry V, Ramsheh MY, Free RC, 
John C, Reeve NF, Miller BE, Tal-Singer R, et al. The sputum 
microbiome is distinct between COPD and health, independent of 
smoking history. Respir Res. 2020 Dec;21(1):183.
https://doi.org/10.1186/s12931-020-01448-3 
Hoffman L, Surette M. What to expect when you’re expectorating: 
cystic fibrosis exacerbations and microbiota. Ann Am Thorac Soc. 
2013 Jun;10(3):249–250.
https://doi.org/10.1513/AnnalsATS.201304-086ED 
Huang YJ, Erb-Downward JR, Dickson RP, Curtis JL, Huff-
nagle GB, Han MK. Understanding the role of the microbiome in 
chronic obstructive pulmonary disease: principles, challenges, and 
future directions. Transl Res. 2017 Jan;179:71–83.
https://doi.org/10.1016/j.trsl.2016.06.007 
Huang YJ, Nariya S, Harris JM, Lynch SV, Choy DF, Arron JR, 
Boushey H. The airway microbiome in patients with severe asthma: 
associations with disease features and severity. J Allergy Clin Immu-
nol. 2015 Oct;136(4):874–884.
https://doi.org/10.1016/j.jaci.2015.05.044 
Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract micro - 
biome and lung inflammation: a two-way street. Mucosal Immunol. 
2017 Mar;10(2):299–306.
https://doi.org/10.1038/mi.2016.108 
Kovaleva OV, Romashin D, Zborovskaya IB, Davydov MM, 
Shogenov MS, Gratchev A. Human lung microbiome on the way 
to cancer. J Immunol Res. 2019 Jul 29;2019:1394191.
https://doi.org/10.1155/2019/1394191 
Kozik AJ, Huang YJ. The microbiome in asthma: Role in patho-
genesis, phenotype, and response to treatment. Ann Allergy Asthma 
Immunol. 2019 Mar;122(3):270–275.
https://doi.org/10.1016/j.anai.2018.12.005 
LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. 
Clin Microbiol Rev. 2010 Apr;23(2):299–323.
https://doi.org/10.1128/CMR.00068-09 
Lloyd CM, Marsland BJ. Lung homeostasis: influence of age, micro-
bes and the immune system. Immunity. 2017 Apr;46(4):549–561. 
https://doi.org/10.1016/j.immuni.2017.04.005 
Loverdos K, Bellos G, Kokolatou L, Vasileiadis I, Giamarellos E, 
Pecchiari M, Koulouris N, Koutsoukou A, Rovina N. Lung micro-
biome in asthma: Current perspective. J Clin Med. 2019 Nov 14; 
8(11):1967. https://doi.org/10.3390/jcm8111967 
Malinowska M, Tokarz-Deptuła B, Deptuła W. [Mikrobiom 
człowieka] (in Polish). Postepy Mikrobiol. 2017;56(1):33–42.
Martinez FJ, Erb-Downward JR, Huffnagle GB. Significance of 
the microbiome in chronic obstructive pulmonary disease. Ann Am 
Thorac Soc. 2013 Dec;10 Supplement:S170–S179.
https://doi.org/10.1513/AnnalsATS.201306-204AW 
Moffatt MF, Cookson WO. The lung microbiome in health and 
disease. Clin Med (Lond). 2017 Dec;17(6):525–529.
https://doi.org/10.7861/clinmedicine.17-6-525 
Noval Rivas M, Crother TR, Arditi M. The microbiome in asthma. 
Curr Opin Pediatr. 2016 Dec;28(6):764–771.
https://doi.org/10.1097/MOP.0000000000000419 
O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, 
immunity and the pathogenesis of chronic lung disease. J Immunol. 
2016 Jun 15;196(12):4839–4847.
https://doi.org/10.4049/jimmunol.1600279 
Ogunrinola GA, Oyewale JO, Oshamika OO, Olasehinde GI. The 
human microbiome and its impacts on health. Int J Microbiol. 2020 
Jun 12;2020:1–7.
https://doi.org/10.1155/2020/8045646 
Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Alm-
qvist C, Bruno A, Bonini S, Bont L, Bossios A, Bousquet J,  et al. 
Viruses and bacteria in acute asthma exacerbations – A GA2LEN- 
-DARE* systematic review. Allergy. 2011 Apr;66(4): 458–468.
https://doi.org/10.1111/j.1398-9995.2010.02505.x 
Paudel KR, Dharwal V, Patel VK, Galvao I, Wadhwa R, Malyla V, 
Shen SS, Budden KF, Hansbro NG, Vaughan A, et al. Role of lung 
microbiome in innate immune response associated with chronic 
lung diseases. Frontiers in Medicine. 2020 Sep 18;7:554.
https://doi.org/10.3389/fmed.2020.00554 
Pulvirenti G, Parisi GF, Giallongo A, Papale M, Manti S, Savasta S, 
Licari A, Marseglia GL, Leonardi S. Lower airway microbiota. 
Front Pediatr. 2019 Sep 27;7:393.
https://doi.org/10.3389/fped.2019.00393 
Ramírez-Labrada AG, Isla D, Artal A, Arias M, Rezusta A, 
Pardo J, Gálvez EM. The influence of lung microbiota on lung car-
cinogenesis, immunity and immunotherapy. Trends Cancer. 2020 
Feb;6(2):86–97.
https://doi.org/10.1016/j.trecan.2019.12.007 
Rogers GB, Bruce KD, Hoffman LR. How can the cystic fibrosis 
respiratory microbiome influence our clinical decision-making? 
Curr Opin Pulm Med. 2017 Nov;23(6):536–543.
https://doi.org/10.1097/MCP.0000000000000419 
Magryś A. 132
Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immu-
nity and host defense by the intestinal microbiota. Front Microbiol. 
2015 Oct 7;6:1085. https://doi.org/10.3389/fmicb.2015.01085 
Simpson JL, Daly J, Baines KJ, Yang IA, Upham JW, Reynolds PN, 
Hodge S, James AL, Hugenholtz P, Willner D, et al. Airway dys-
biosis: Haemophilus influenzae and Tropheryma in poorly controlled 
asthma. Eur Respir J. 2016 Mar;47(3):792–800.
https://doi.org/10.1183/13993003.00405-2015 
Sommariva M, Le Noci V, Bianchi F, Camelliti S, Balsari A, 
Tagliabue E, Sfondrini L. The lung microbiota: role in maintaining 
pulmonary immune homeostasis and its implications in cancer devel-
opment and therapy. Cell Mol Life Sci. 2020 Jul;77(14):2739–2749. 
https://doi.org/10.1007/s00018-020-03452-8 
Surette MG. The cystic fibrosis lung microbiome. Ann Am Thorac 
Soc. 2014 Jan;11 Suppl 1:S61–S65.
https://doi.org/10.1513/AnnalsATS.201306-159MG
Sverrild A, Kiilerich P, Brejnrod A, Pedersen R, Porsbjerg  C, 
Bergqvist A, Erjefält JS, Kristiansen K, Backer V. Eosinophilic air-
way inflammation in asthmatic patients is associated with an altered 
airway microbiome. J Allergy Clin Immunol. 2017 Aug;140(2): 
407–417.e11. https://doi.org/10.1016/j.jaci.2016.10.046 
Taylor SL, Leong LEX, Choo JM, Wesselingh S, Yang IA, 
Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, et al. 
Inflammatory phenotypes in patients with severe asthma are associa-
ted with distinct airway microbiology. J Allergy Clin Immunol. 2018 
Jan;141(1):94–103.e15. https://doi.org/10.1016/j.jaci.2017.03.044 
Toraldo DM, Conte L. Influence of the lung microbiota dysbiosis 
in chronic obstructive pulmonary disease exacerbations: the contro-
versial use of corticosteroid and antibiotic treatments and the role of 
eosinophils as a disease marker. J Clin Med Res. 2019;11(10):667–675. 
https://doi.org/10.14740/jocmr3875 
Wang J, Li F, Tian Z. Role of microbiota on lung homeostasis and 
diseases. Sci China Life Sci. 2017 Dec;60(12):1407–1415.
https://doi.org/10.1007/s11427-017-9151-1 
Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, 
Tal-Singer R, Johnston SL, Ramsheh MY, Barer MR, et al. Lung 
microbiome dynamics in COPD exacerbations. Eur Respir J. 2016 
Apr;47(4):1082–1092. https://doi.org/10.1183/13993003.01406-2015
Xu N, Wang L, Li C, Ding C, Li C, Fan W, Cheng C, Gu B. Micro-
biota dysbiosis in lung cancer: evidence of association and potential 
mechanisms. Transl Lung Cancer Res. 2020 Aug;9(4):1554–1568.
https://doi.org/10.21037/tlcr-20-156 
Yang X, Feng H, Zhan X, Zhang C, Cui R, Zhong L, Ying S, Chen Z. 
Early-life vancomycin treatment promotes airway inflammation and 
impairs microbiome homeostasis. Aging (Albany NY). 2019 Apr 13; 
11(7):2071–2081. https://doi.org/10.18632/aging.101901
